source
- Pfizer CEO says company has already completed its largest deals, no further acquisitions plannedPfizer chief Albert Bourla addressed investors from the New York Stock Exchange floor, noting that the company has already executed its biggest transactions and has roughly $6 billion earmarked for…
- Merck’s anti‑TL1A antibody tulisokibart fails Phase 2b in systemic sclerosis lung disease but succeeds in hidradenitis suppurativaMerck reported mixed Phase 2b results for its anti‑TL1A monoclonal antibody tulisokibart, acquired in the 2023 Prometheus Biosciences purchase. In patients with systemic sclerosis‑associated inter…